Novo Nordisk Forecasts Sales Decline, Stock Plummets Amid Market Headwinds
February 4, 2026, 3:51 pm
home.barclays
Employees: 10001+
Novo Nordisk projects a substantial 5-13% decline in 2026 sales and profit. This forecast sparked a sharp stock tumble. Key drivers include intense U.S. pricing pressure and fierce competition from Eli Lilly. Loss of exclusivity for Wegovy and Ozempic in vital international markets also impacts revenue. Despite a strong initial U.S. launch of the oral Wegovy pill, its positive effect is insufficient to counter these significant headwinds. The company aims for long-term growth by prioritizing patient affordability, introducing new therapies, and expanding global reach, yet faces a challenging short-term outlook. Leadership changes add to market uncertainty.
Copenhagen-based Novo Nordisk faces a significant financial challenge. Its stock plummeted after warning of declining sales and profit. American Depositary Shares dropped 14%. Copenhagen-listed shares fell 18%. This wiped out previous gains. The company sees sales and operating profit falling 5% to 13% in 2026. This outlook disappointed analysts.
U.S. market dynamics drive much of this pressure. Novo Nordisk expects a sales decline in its largest market. Lower drug prices are a key factor. A landmark deal with the Trump administration impacts profitability. This agreement cuts prices for Medicare and Medicaid beneficiaries. It also offers direct consumer discounts via TrumpRx.gov. These measures increase access but reduce per-unit revenue. Competition from compounding pharmacies also pressures pricing. These pharmacies sell cheaper versions of active ingredients.
The competitive landscape intensifies. U.S. rival Eli Lilly poses a formidable threat. Lilly's weight-loss drug tirzepatide, sold as Mounjaro and Zepbound, offers strong efficacy. It surpassed Novo Nordisk in U.S. market share. Lilly plans its own oral weight-loss pill launch in early 2026. This further heightens competition in the lucrative GLP-1 market. Investors scrutinize Novo's strategy. They want to see market share regained.
International markets add to the headwinds. Semaglutide, the active ingredient in Wegovy and Ozempic, faces patent expiry. This impacts sales in critical markets. Canada, Brazil, and China will see generic competition in 2026. This loss of exclusivity compounds pricing challenges. Global sales growth ex-U.S. remains positive, but not enough to offset declines.
Novo Nordisk launched its oral Wegovy pill in the U.S. in January. Initial uptake was promising. Over 170,000 patients started the pill in four weeks. This oral GLP-1 treatment marks a significant advance. The starting dose sells for $149. This is a fraction of the injectable version's cost. Yet, even this strong launch cannot overcome broader pricing pressures. The current business faces substantial price hits.
The company's 2025 performance showed strain. Sales rose 10%, operating profit 6%. This aligned with lowered guidance. Novo Nordisk cut its guidance multiple times last year. This reflected U.S. market difficulties. Stock prices fell 46.5% in 2025. This marked a historic low. Leadership changes accompanied this turbulence. A non-Danish CEO took the helm. A former CEO became board chair. These moves stirred corporate governance discussions.
Fourth-quarter 2025 results offered mixed signals. Net sales hit 79.1 billion Danish kroner ($12.5 billion). This slightly exceeded analyst estimates. Operating profit was 31.7 billion kroner. It fell 14% year-on-year. Ozempic, a top seller, saw 1% sales growth. Wegovy sales climbed 17%. These gains are insufficient for the challenging 2026 outlook.
Novo Nordisk is banking on future innovations. It plans more Wegovy rollouts in 2026. A higher 7.2 mg dose will also launch in several countries. The next-generation injectable, CagriSema, is in development. These new products aim to recapture market share. They are crucial for long-term growth. The company emphasizes affordability. It sees short-term pain for long-term patient access.
The CEO acknowledges the difficult path ahead. He stated conditions "go down before it comes back up." This reflects the pricing headwinds. The goal remains expanding GLP-1 market reach. Millions of patients need these products. Making them affordable is a priority. This strategy incurs immediate financial costs. But it promises future volume growth.
Investor sentiment remains cautious. Some analysts suggest the guidance acts as a "kitchen sink" moment. It clears expectations for a reset. Others recall similar optimism from 2025. Previous guidance cuts were not beaten. The recovery path is uncertain. Will it be a rapid "Nike swoosh" or a gradual "U-shaped" rebound? Only time will tell. Novo Nordisk navigates a highly competitive, rapidly evolving market. Its future depends on strategic execution and product innovation.
Copenhagen-based Novo Nordisk faces a significant financial challenge. Its stock plummeted after warning of declining sales and profit. American Depositary Shares dropped 14%. Copenhagen-listed shares fell 18%. This wiped out previous gains. The company sees sales and operating profit falling 5% to 13% in 2026. This outlook disappointed analysts.
U.S. market dynamics drive much of this pressure. Novo Nordisk expects a sales decline in its largest market. Lower drug prices are a key factor. A landmark deal with the Trump administration impacts profitability. This agreement cuts prices for Medicare and Medicaid beneficiaries. It also offers direct consumer discounts via TrumpRx.gov. These measures increase access but reduce per-unit revenue. Competition from compounding pharmacies also pressures pricing. These pharmacies sell cheaper versions of active ingredients.
The competitive landscape intensifies. U.S. rival Eli Lilly poses a formidable threat. Lilly's weight-loss drug tirzepatide, sold as Mounjaro and Zepbound, offers strong efficacy. It surpassed Novo Nordisk in U.S. market share. Lilly plans its own oral weight-loss pill launch in early 2026. This further heightens competition in the lucrative GLP-1 market. Investors scrutinize Novo's strategy. They want to see market share regained.
International markets add to the headwinds. Semaglutide, the active ingredient in Wegovy and Ozempic, faces patent expiry. This impacts sales in critical markets. Canada, Brazil, and China will see generic competition in 2026. This loss of exclusivity compounds pricing challenges. Global sales growth ex-U.S. remains positive, but not enough to offset declines.
Novo Nordisk launched its oral Wegovy pill in the U.S. in January. Initial uptake was promising. Over 170,000 patients started the pill in four weeks. This oral GLP-1 treatment marks a significant advance. The starting dose sells for $149. This is a fraction of the injectable version's cost. Yet, even this strong launch cannot overcome broader pricing pressures. The current business faces substantial price hits.
The company's 2025 performance showed strain. Sales rose 10%, operating profit 6%. This aligned with lowered guidance. Novo Nordisk cut its guidance multiple times last year. This reflected U.S. market difficulties. Stock prices fell 46.5% in 2025. This marked a historic low. Leadership changes accompanied this turbulence. A non-Danish CEO took the helm. A former CEO became board chair. These moves stirred corporate governance discussions.
Fourth-quarter 2025 results offered mixed signals. Net sales hit 79.1 billion Danish kroner ($12.5 billion). This slightly exceeded analyst estimates. Operating profit was 31.7 billion kroner. It fell 14% year-on-year. Ozempic, a top seller, saw 1% sales growth. Wegovy sales climbed 17%. These gains are insufficient for the challenging 2026 outlook.
Novo Nordisk is banking on future innovations. It plans more Wegovy rollouts in 2026. A higher 7.2 mg dose will also launch in several countries. The next-generation injectable, CagriSema, is in development. These new products aim to recapture market share. They are crucial for long-term growth. The company emphasizes affordability. It sees short-term pain for long-term patient access.
The CEO acknowledges the difficult path ahead. He stated conditions "go down before it comes back up." This reflects the pricing headwinds. The goal remains expanding GLP-1 market reach. Millions of patients need these products. Making them affordable is a priority. This strategy incurs immediate financial costs. But it promises future volume growth.
Investor sentiment remains cautious. Some analysts suggest the guidance acts as a "kitchen sink" moment. It clears expectations for a reset. Others recall similar optimism from 2025. Previous guidance cuts were not beaten. The recovery path is uncertain. Will it be a rapid "Nike swoosh" or a gradual "U-shaped" rebound? Only time will tell. Novo Nordisk navigates a highly competitive, rapidly evolving market. Its future depends on strategic execution and product innovation.